The onset of puberty is marked by breast development and menstruation in girls. Tanner stage 3 breast development means appearance of the breast bud marks the onset of pubertal development. 3 The most common mechanism of progressive precocious puberty is the early activation of pulsatile gonadotrophin releasing hormone secretion which results in maturation of hypothalmo-pituitary ovarian axis which activates maturation of hormone responsive tissue such as breast, bones, pubic hair and endometrium. These girls have normal ovulation, menstruation and reproductive capacity. 4 Isolated sexual precocity of unknown etiology carries no increased risk of mortality, however, distinguishing between children with idiopathic CPP and rare patient with a CNS, adrenal or ovarian tumor is important because the latter group may be at risk for tumor related complication. Children with precocious puberty may be stressed because of physical and hormonal changes; they are too young to understand. 5 Going through puberty early can also be difficult for a child emotionally and socially. For example, girls with precocious puberty may be confused or embarrassed about physical changes such as getting their periods or having enlarged breasts well before any of their peers 5 . In case with progressive precocious puberty, they may present with adverse psycosocial outcomes, early menarche and short stature, because of early epiphyseal fusion 6 .
Here we present a case of a female child of precocious puberty.
Case Report:
A female child of 04 years old was brought by her parents to the Obstetrics and Gynaecology out patient 
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Hospital having bilateral enlargement of breast, presence of pubic hair for one year and history of periodic bleeding per vagina for three months. According to the statement of patient's mother her child was alright one year back. Her milestones of development were normal. But she noticed that breast was enlarging gradually and there is growth of pubic hair. Her mother also noticed that the girl was suffering from per vaginal bleeding which evolved into monthly regular cycles of three to four days. She had no history of birth injury, head injury, encephalitis, headache or seizure.
1.9 x 1.0 cm) and follicles were present in each ovarian parenchyma , uterus was measuring about 4.7 x 1.3 cm (L x AP). Tumor markers such as carcinoembryonic antigen (CEA), CA 18.7, alphafetoprotein, and human chorionic gonadotropin (HCG) were negative. MRI of brain, shows changes due to hypothalamic hamartoma. After getting all investigations we came to conclusion this girl suffered from precocious puberty, which is central secondary to hypothalmic hamartoma. After counselling with patient's guardian we start our treatment. We prescribed GnRH agonist, Inj. Decapeptyl 3.75 mg every 4 weeks. The drug is to be continued for 11 years of her age. After giving treatment, follow up was done after one month, she developed menstruation, pubic and axillary hair was increased But after two year follow-up, with subsidence in size of the General physical examination of the patient was within normal limit. Her height was 100 cm, her weight 17 kg and skin pigmentation absent. But examination of breast revealed that her both the breast was enlarged and firm in consistency. Nipple and areola were developed. No discharge was present. Axillary and pubic hair was long, curved and dark. On per abdominal examination no palpable lump was present.
She had normal hematological and biochemical profiles, however, the hormonal analysis revealed pubertal response of gonadotropins with luteinizing hormone (LH) of 2.30 mI/ mL (N < 0.6 mIU / mL), follicle-stimulating hormone (FSH) of 4.98 mIU / mL (N < 0.6 mIU / mL), and estradiol (E2) of 9.6 pg / mL (N < 5 pg / mL), with normal thyroid functions. X ray of the left wrist revealed bone age was greater than chronological age. USG showed ovaries were prominent (right ovary-2.8 x 1.0 cm and left ovary- hypothalamic hamartoma, secondary sexual characters, reversed and monthly menstrual cycles regressed.
Discussion:
Precocious puberty is an unusually early onset of puberty, statistically defined as -2.5 to 3.0 SDs below the average age of onset of puberty in healthy children 6 . It is a relatively rare condition. The Gonadotrophin dependent type (GDPP) also known as central precocious puberty is the most common subtype and is characterized by an early maturation of the hypothalamic-pituitary-gonadal axis. This is much more common in girls than boys. Here the pattern and timing of pubertal events progresses in the normal sequence. 6 Eighty to ninety percent of GDPP will have no identifiable cause (idiopathic GDPP) and this condition will have a striking female predominance 7, 8 . The other important causes include CNS tumors, trauma, infections, primary hypothyroidism, hydrocephalus, cysts etc 7 .
Hypothalamic hamartoma is a relatively rare congenital malformation usually associated with central precocious puberty and gelastic seizures. This tumor is composed of redundant brain tissue with a haphazard assembly of neurons, nerve fibers, and neuroglial cells in inappropriate distributions and proportions 8 .The association of hypothalamic hamartoma with precocious puberty has long been recognized. In fact hypothalamic hamartoma is one of the most common cerebral lesions associated with precocious puberty 9 .
Children with precocious puberty due to hypothalamic hamartomas usually present before four years of age 10 .Although the mechanism for precocious puberty is not known, the prevailing view is that hypothalamic hamartomas contain ectopic Luteinizing Hormone Releasing Hormone (LHRH) neurosecretory neurons which are unrestrained by the normal negative feedback mechanisms and produce secretory bursts of LHRH 11 .
Our patient had a normal pattern of pubertal growth, a quicker skeletal maturity, and an elevated level of Luteinizing hormone (LH). All these findings are characteristic of GDPP or central precocious puberty 12 .MRI is the primary imaging modality for detection of Hypothalamic hamartomas allowing better tissue characterization and greater anatomic details 12 .The imaging features most commonly consist of a hypothalamic mass isointense to grey matter on T1W sequence, and increased signal intensity on T2W and FLAIR (fluid attenuated inversion Recovery) sequence 8 .The MRI of our patient revealed all of these features.
Medical treatment with long-acting GnRH agonists is the first choice of treatment in patients with CPP due to Hypothalamic hamartoma 13 .In particular, depot preparations ensure an adult height within the genetic height potential with normal body proportions, bone density and reproductive function 14 .Surgical resection of the hypothalamic hamartoma is indicated only in cases of progressive neurological deficit, hydrocephalus, and progressive enlargement of the mass and intractable seizures 15 .
Conclusion:
Thorough history taking and careful examination is required to determine the possible causes of precocious puberty, however, it is often vague. Additional evaluation should include hormonal assays and bone age assessment (E2, LH, and TSH). If a randomly measured level of LH is in the pubertal range, an MRI brain should be obtained. A pelvic ultrasound scan is required to rule out an ovarian tumour or cyst, mainly if the E2 level is elevated. A GnRH or GnRHagonist stimulation test is the gold standard for diagnosing CPP, and is recommended to assess the activation of the gonadotropic axis, for predicting the progression of puberty. In case of progressive CPP, treatment with a depot GnRH agonist is suggested and is generally continued for 11 years, even though the best duration of therapy is undecided.
